U.S. markets close in 5 hours 23 minutes
  • S&P 500

    4,368.31
    -64.68 (-1.46%)
     
  • Dow 30

    34,117.35
    -467.53 (-1.35%)
     
  • Nasdaq

    14,746.92
    -297.05 (-1.97%)
     
  • Russell 2000

    2,182.40
    -54.47 (-2.44%)
     
  • Crude Oil

    70.45
    -1.52 (-2.11%)
     
  • Gold

    1,764.90
    +13.50 (+0.77%)
     
  • Silver

    22.42
    +0.08 (+0.35%)
     
  • EUR/USD

    1.1726
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.3240
    -0.0460 (-3.36%)
     
  • GBP/USD

    1.3663
    -0.0074 (-0.54%)
     
  • USD/JPY

    109.5300
    -0.3650 (-0.33%)
     
  • BTC-USD

    43,951.74
    -3,570.73 (-7.51%)
     
  • CMC Crypto 200

    1,094.80
    -39.59 (-3.49%)
     
  • FTSE 100

    6,889.74
    -73.90 (-1.06%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

Given this risk, we thought we'd take a look at whether XBiotech (NASDAQ:XBIT) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

See our latest analysis for XBiotech

How Long Is XBiotech's Cash Runway?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When XBiotech last reported its balance sheet in December 2020, it had zero debt and cash worth US$237m. Looking at the last year, the company burnt through US$69m. So it had a cash runway of about 3.4 years from December 2020. There's no doubt that this is a reassuringly long runway. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is XBiotech's Cash Burn Changing Over Time?

Although XBiotech had revenue of US$44m in the last twelve months, its operating revenue was only US$44m in that time period. Given how low that operating leverage is, we think it's too early to put much weight on the revenue growth, so we'll focus on how the cash burn is changing, instead. Remarkably, it actually increased its cash burn by 261% in the last year. Given that sharp increase in spending, the company's cash runway will shrink rapidly as it depletes its cash reserves. In reality, this article only makes a short study of the company's growth data. You can take a look at how XBiotech has developed its business over time by checking this visualization of its revenue and earnings history.

How Easily Can XBiotech Raise Cash?

While XBiotech does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

XBiotech has a market capitalisation of US$577m and burnt through US$69m last year, which is 12% of the company's market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

Is XBiotech's Cash Burn A Worry?

On this analysis of XBiotech's cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. Its important for readers to be cognizant of the risks that can affect the company's operations, and we've picked out 1 warning sign for XBiotech that investors should know when investing in the stock.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.